Join us at Fierce Biotech Week 2025

October 7-9, 2025 • Boston, MA

JOIN US

The Premier Biotech Innovation and Networking Event

WHAT TO EXPECT AT THE EVENT:

Fierce Biotech Week, presented by Fierce Biotech & Fierce Pharma, brings together over 1,100 biotech and pharma leaders for three days of high-impact learning, networking, and innovation at the Encore Boston Harbor Hotel.

Designed for executives in drug development, clinical research, business development & licensing, TMF management, and communications, the event focuses on advancing pipelines through scientific breakthroughs, streamlining clinical operations, examining deal structures, navigating the investment landscape, and fostering new partnerships to accelerate the future of healthcare.

MEET US AT BOOTH #306

We bring deep expertise in biologics drug discovery and development, including ADC engineering and conjugation, in vitro and in vivo assays, and integrated platforms from early concept to IND-enabling studies. Connect with Carlo Petruzziello and Yuzhou Xu, from ChemPartner’s Business Development team, to discuss how our collaborative approach and scientific expertise can accelerate your next biologics breakthrough.

ATTEND OUR PRESENTATION ON OCTOBER 8th AT 9:45 AM

If you are planning to attend the R&D Session on October 8th, we invite you to our presentation at 9:45 am, titled “Preclinical Advancement of HER2/TROP2 Bispecific Antibody-Drug Conjugates”, presented by Yinfei Yin, our Managing Director of ChemPartner US.

Networking Event

Join us for the ChemPartner Social Hour!

While in Boston, join us for a ChemPartner-sponsored networking and happy hour event at the Alexandria!

Location:

The Alexandria Conference Center

400 North Beacon St., Watertown, MA

Time:

Thursday, October 9, 2025

3:30-5:30 PM EST

RSVP now

View our Abstract

Bispecific Antibody-drug Conjugates (bsADCs) Targeting HER2 and TROP2

Abstract:

ChemPartner accelerates biologic drug discovery and development from early concept to IND-enabling studies by using comprehensive and integrated platforms. We present a preclinical advancement case study of bispecific antibody-drug conjugates (bsADCs) targeting HER2 and TROP2, co-expressed tumor antigens in solid cancers.

Employing monovalent IgG1 scaffolds from trastuzumab and sacituzumab, conjugated to MMAE, the constructs exhibited dual-specific binding, rapid internalization, and sub-nanomolar cytotoxicity in tested cell lines with heterogeneous antigen expression.

Xenograft models confirmed enhanced antitumor efficacy and pharmacokinetics over monospecific counterparts, highlighting dual-targeting’s therapeutic potential.

Let’s Connect

Contact us

7 + 7 =

Headquarters

1F & 3F, Block A
2829 JinKe Road
Zhangjiang Hi-Tech Park
PuDong New Area
Shanghai China, 201203

w

Contact Us

China: +86 21 5132 0088
US: +1 650 419 9974
Europe: +45 4586 9000

contact@chempartner.com